Member Info for doze

By not evaluating the LFT on equal terms a year ago Howzaty. It is scientists who should have seen the flawed procedure. I could not have produced affimers etc but I did see the flawed procedure.

I would like to say that the scientists have let AVCT down big time.

I may be shot down but that might be the first time the evaluation has done pcr on the captured proteins using the affimer reagent. It is only fair to use the same technique for comparison. Of course for the LFT to be used as intended the samples collected-probably anterior nasal, will not be subjected to a pcr procedure. However the passing of evaluation which could have been done early last year if this evaluation technique had been used will I hope allow the pragmatic use of LFTs which capture the most infectious. Field trials will not in my opinion find that many infected but every one infectious detected is going to prevent new outbreaks.

I think they have doctored it Cashless, it was definitely Smith.

SoniaD; I don't know why you get worked up, the german predictive text will come up with a W and S Korea with B and K-all good, we are going global. Not worth arguing with a computer anyway, they have no empathy.

I prefer that Cytiva might still be in the fold seethree as the numbers will be far greater if they are. If the lower profile was at their request and we are still using their strips all could be progressing quite well.

I am hoping the Royal Mail will be sending out free sovereign tests and a good data base is built up on infection rates going to zero as a result.

If he is going to deliver now it is down to a gauranteed order from the UK and the consortium tie up as it has been no p.i.s.s up in a brewery getting a test to market, it required assistance.

They will promote their expertise PL They would not have grown without being involved in the decisions of manufacturers
https://www.cytivalifesciences.com/en/us/news-center/introducing-cytiva-global-life-sciences-leader-10001
says: “Our foundation of scientific expertise, our team, and our solid customer base place Cytiva in the right position to invest, develop, and accelerate growth in the industry. Our passion for helping bring life-changing therapies to patients is unwavering, and we will continue to introduce innovative technologies to the market which improve productivity for our customers.”

This link was sent to me and I found quite instructive especially the take in most of the recent comments.
https://www.youtube.com/watch?v=iSVy1b-RyVM

That is interesting. They could have objected to the attention they were getting with AS putting them into rns' too prominently.

Livedata; it says......."shortly initiate further clinical validation".........and I would have thought that depended on this being successful........."Clinical evaluation of the lateral flow test is currently being carried out at a hospital in mainland Europe"
so the government to plan tests in the post must have their own process.

That is what is under AVCT control Timster. What the government has done is the completed process hopefully.

....and that is what I would like to happen as I can only see roll out as the proper validation of affimers.

I've said that myself goldtrig. I was trying to justify my previous thoughts by suggesting the sovereign test could come out even if AVCT do not get evaluation out in time over the channel.

Timster, thanks for managing my expectations, nothing is nailed on as it says in the rns. I wonder whether the sovereign test can be subject to different rules to get that out.

I think the S&S is a fait accompli for the sovereign test or the government is going to look foolish. S&S in an AVCT rns is what cannot be predicted at the moment as I think that will be delivered via the Mologic affimer test.

Good to see this thread has grasped the most infectious period is all that matters; all the other test types have failed something that spreads like a cold. The regulations have been tailored to our test. Boris is all set to grandstand a successful opening up of business and data as exhibited by the covid free English to be used by AVCT to sell globally-I hope.

I don't think the therapy side will add much revenue to the TU. In my opinion the TU could not be released before confirmation of AVCT affimers being used in a UK approved by the regulators sovereign test. A lot of costs have been incurred putting the test together for the government and it would be unfair not to have a mention within a roll out announcement coming at the same time as the TU.

It was ODX who lit the fuse for us. Anyway we are all waiting for the fog to clear DOH.